Dyadic to Develop Biosimilars Using CHO-Challenging Expression System

BioProcess International

by Dan Stanton, Tuesday, June 5, 2018

Dyadic to Develop Biosimilars Using CHO-Challenging Expression System

Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company has begun developing a pipeline of biosimilars using a fungal expression system it says achieves much higher productivity than CHO cell lines.

Over the past 18 months, Dyadic has generated data demonstrating MAb expression level of nine grams per liter in 90 hours – or 2.4 grams per liter per day – using fed batch technology that is based on low cost defined media and glucose feeding.

"This expression level appears to already far exceed that of CHO cells in grams per liter per day, uses very low cost defined media and eliminates two viral inactivation steps," while having similar binding kinetic to Mabs made using CHO cells.

Read the full article at the link below:

http://www.bioprocessintl.com/bioprocess-insider/upstream-downstream-processing/dyadic-developing-biosimilars-using-cho-challenging-expression-tech/

For more information, contact:

Ping Rawson, Chief Accounting Officer

Dyadic International, Inc.

[email protected]